triple agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-08. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Depending on the experimental conditions, cycloaddition of acetone and ketene produces either β-isovalerolactone or 4,4-dimethyloxetan-2-one, both of which hydrolyze under basic conditions to yield the conjugate base of HMB. The haloform reaction provides another pathway to HMB involving the exhaustive halogenation of the methyl-ketone region of diacetone alcohol with sodium hypobromite or sodium hypochlorite; Diacetone alcohol is readily available from the aldol condensation of acetone. An organometallic approach to HMB involves the carboxylation of tert-butyl alcohol with carbon monoxide and Fenton's reagent (hydrogen peroxide and ferrous iron). Alternatively, HMB can be prepared through microbial oxidation of β-methylbutyric acid by the fungus Galactomyces reessii.
Tenatoprazole (TU-199), an imidazopyridine proton pump inhibitor, is a novel compound that has been designed as a new chemical entity with a substantially prolonged plasma half-life (7 hours), but otherwise has similar activity as other PPIs. The difference in the structural backbone of tenatoprazole compared to benzimidazole PPIs, is its imidazo[4,5-b]pyridine moiety, which reduces the rate of metabolism, allowing a longer plasma residence time but also decreases the pKa of the fused imidazole N as compared to the current PPIs. Tenatoprazole has the same substituents as omeprazole, the methoxy groups at position 6 on the imidazopyridine and at position 4 on the pyridine part as well as two methyl groups at position 3 and 5 on the pyridine. The bioavailability of tenatoprazole is double for the (S)-(−)-tenatoprazole sodium salt hydrate form when compared to the free form in dogs. This increased bioavailability is due to differences in the crystal structure and hydrophobic nature of the two forms, and therefore its more likely to be marketed as the pure (S)-(−)-enantiomer.
There are 203 possible ways that the exchangeability parameters can be restricted to form sub-models of GTR, ranging from the JC69 and F81 models (where all exchangeability parameters are equal) to the SYM model and the full GTR (or REV) model (where all exchangeability parameters are free). The equilibrium base frequencies are typically treated in two different ways: 1) all
Sources: en.wikipedia.org
==== Film, stage, and television influenced by Jung's ideas ==== Federico Fellini brought to the screen exuberant imagery shaped by his encounter with Jung's ideas, especially Jungian dream interpretation. Fellini preferred Jung to Freud because Jungian analysis defined the dream not as a symptom of a disease that required a cure but rather as a link to archetypal images shared by all of humanity. Stanley Kubrick's 1987 film Full Metal Jacket has an underlying theme about the duality of man. In one scene, a colonel asks a soldier, "You write 'Born to Kill' on your helmet and you wear a peace button. What's that supposed to be, some kind of sick joke?" The soldier replies, "I think I was trying to suggest something about the duality of man, sir...the Jungian thing, sir." (The colonel in this scene is played by the brother of famed Jungian psychologist Marion Woodman.) In the 1994 Frasier episode, "Frasier Crane's Day Off", Niles fills in for his brother, declaring: "Although I feel perfectly qualified to fill Frasier's radio shoes, I should warn you that while Frasier is a Freudian, I am a Jungian. So there'll be no blaming Mother today." Robert Eggers's 2019 psychological thriller The Lighthouse has elements strongly influenced by Jung's work, with Eggers hoping that "it's a movie where both Jung and Freud would be furiously eating their popcorn".
=== Screening === In China, Web-technologies were used to direct individuals to appropriate resources. Infrared thermal cameras are used to detect individuals with fever. Machine learning has been used for diagnosis and risk prediction.
== Reactions == It dissolves in water to give a mildly alkaline solution. It is insoluble in acetone and alcohols. Ammonium bicarbonate decomposes above about 36 °C into ammonia, carbon dioxide, and water in an endothermic process and so causes a drop in the temperature of the water:
Sources: en.wikipedia.org
==== LL Cool J ==== Ice-T had a feud with LL Cool J in the late 1980s and early 1990s. Apparently, this was instigated by LL's claim to be "the baddest rapper in the history of rap itself". Ice-T recorded disses against LL on his 1988 album Power. On the album was the track, "I'm Your Pusher", in which a rap music addict declines to buy an LL Cool J record. In the book Check the Technique: Liner Notes for Hip-Hop Junkies, Ice-T said that the song "Girls L.G.B.N.A.F." was also intended as a diss to LL Cool J, by making a crude song to contrast with the love songs that LL was making at the time. On LL's response, "To da Break of Dawn" in 1990, he dissed Kool Moe Dee (whose feud with LL was far more publicized) as well as MC Hammer. He then devoted the third verse of the song to dissing Ice-T, mocking his rap ability ("take your rhymes around the corner to rap rehab"), his background ("before you rapped, you was a downtown car thief"), and his style ("a brother with a perm deserves to get burned"). He also suggested that the success of Power was due to the appearance of Ice-T's girlfriend Darlene on the album cover. Ice-T appeared to have ignored the insults and he had also defended LL Cool J after his arrest in the song "Freedom of Speech". In August 2012, Ice-T said that the rivalry was "never serious" and that he needed a nemesis to create "an exciting dispute".
== Education == Özergin completed a B.S. (1987) and M.S. (1989) in chemical engineering at Boğaziçi University. She earned a Ph.D. in chemical engineering at University of Manchester in 1992. Özergin researched Streptomyces coelicolor antibiotic production and bioreactors. Her dissertation was titled Study of antibiotic synthesis by free and immobilised streptomyces coelicolor a3(2). Özergin's doctoral advisor was Ferda Mavituna.
fractionation A separation process in which a particular quantity of a mixture is divided during a phase transition into a number of smaller quantities, known as fractions, for which the chemical composition varies according to a gradient. Fractionation exploits subtle differences in some specific property (e.g. mass, boiling point, solubility, etc.) between the mixture's component compounds, making it possible to isolate more than two components of a mixture at the same time. There are many varieties of fractionation employed in many branches of science and technology.
, respectively. Their ratio is not equal to the equilibrium constant, which implies that thermodynamics does not constrain the ratio of the maximal rates. This explains that enzymes can be much "better catalysts" (in terms of maximal rates) in one particular direction of the reaction. One can also derive the two Michaelis constants
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.